表紙
市場調查報告書

市場焦點:Waldenstrom氏巨球蛋白血症 (WM)

Market Spotlight: Waldenstrom Macroglobulinemia (WM)

出版商 Datamonitor Healthcare 商品編碼 939986
出版日期 內容資訊 英文 34 Pages
商品交期: 最快1-2個工作天內
價格
市場焦點:Waldenstrom氏巨球蛋白血症 (WM) Market Spotlight: Waldenstrom Macroglobulinemia (WM)
出版日期: 2020年04月17日內容資訊: 英文 34 Pages
簡介

本報告提供全球Waldenstrom氏巨球蛋白血症 (WM) 治療藥臨床實驗形勢與市場趨勢預測相關分析,彙整疾病概要和流行病學的預測 (今後10年份),目前主要治療藥 (已上市/開發中產品) 和臨床實驗的進展,目前未滿足需求和未來的市場機會,臨床實驗/市場將來相關專家的見解等資訊,為您概述為以下內容。

概要

概要

疾病的背景情況

治療方法

  • 化療
  • 標靶藥物
  • 生物學的療法或免疫療法
  • 血漿替換
  • 幹細胞移植(SCT)

流行病學

成藥

開發平台藥物

最近的活動和分析師的意見

  • Brukinsa (2019年12月6日)
  • Mavorixafor (2019年7月7日)

法規上主要的動向

  • 領導Imbruvica (Janssen):歐洲的CLL市場擴大

成功的可能性

母體專利

商機

臨床實驗環境

  • 臨床試驗贊助者的分類:各狀況
  • 臨床試驗贊助者的分類:各期
  • 目前的趨勢

參考文獻

  • 處方藥的資訊

附錄

目錄
Product Code: DMKC0183867

This Market Spotlight report covers the Waldenstrom Macroglobulinemia market, comprising key marketed and pipeline drugs, probability of success, clinical trials, recent events and analyst opinion, patent information, a 10-year disease incidence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2017, there were approximately 5,330 incident cases of Waldenstrom macroglobulinemia (WM) in people aged 40 years and over worldwide, and forecasts that number to increase to 6,920 incident cases by 2026. It is estimated that the majority of diagnosed cases worldwide were in males in 2017. Worldwide, the incidence of WM is highest among individuals aged 60-79 years.
  • Imbruvica, a small molecule tyrosine kinase inhibitor, is the only drug approved by the FDA for WM.
  • The majority of industry-sponsored drugs in active clinical development for WM are in Phase II, with only one drug in Phase III. Therapies in development for WM focus on targets such as p110 delta/PIK3CD, PI3K/AKT pathway, proteasome, and Bruton's tyrosine kinase. These drugs are administered via the oral, intravenous, and subcutaneous routes.
  • The overall likelihood of approval of a Phase I hematologic cancer asset is 9.9%, and the average probability a drug advances from Phase III is 59.4%. Drugs, on average, take 8.8 years from Phase I to approval, compared to 9.3 years in the overall oncology space.
  • There have been three licensing and asset acquisition deals involving WM drugs during 2014-19. The collaboration agreement signed in 2014 between Genmab and Novartis for $50m, pursuant to which Genmab agreed for a conditional transfer of the Arzerra (ofatumumab) collaboration with GlaxoSmithKline to Novartis in oncology indications, was the largest deal.
  • The distribution of clinical trials across Phase I-IV indicates that almost all trials for WM have been in the early and mid-phases of development, with 95% of trials in Phase I-II, and only 5% in Phase III-IV.
  • The US has a substantial lead in the number of WM clinical trials globally. The UK and France lead the major EU markets, while China has the top spot in Asia.
  • Takeda has the highest number of completed clinical trials for WM, with 11 trials. Bristol-Myers Squibb and Takeda lead industry sponsors with the highest overall number of clinical trials for WM, followed by Johnson & Johnson.

TABLE OF CONTENTS

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Chemotherapy
  • Targeted drugs
  • Biological therapy or immunotherapy
  • Plasmapheresis
  • Stem cell transplantation (SCT)

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

  • Brukinsa for WM (December 16, 2019)
  • Mavorixafor for WM (July 17, 2019)

KEY REGULATORY EVENTS

  • Janssen's Imbruvica Leads CLL Market Expansion In Europe

PROBABILITY OF SUCCESS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Recent events

BIBLIOGRAPHY

  • Prescription information

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in incident cases of WM, 2017-26
  • Figure 2: Incident cases of WM, by age, 2017
  • Figure 3: Overview of pipeline drugs for WM in the US
  • Figure 4: Pipeline drugs for WM, by company
  • Figure 5: Pipeline drugs for WM, by drug type
  • Figure 6: Pipeline drugs for WM, by classification
  • Figure 7: Brukinsa for WM (December 16, 2019): Phase III - ASPEN (vs. Ibrutinib)
  • Figure 8: Probability of success in the WM pipeline
  • Figure 9: Parent patents in WM
  • Figure 10: Clinical trials in WM
  • Figure 11: Top 10 drugs for clinical trials in WM
  • Figure 12: Top 10 companies for clinical trials in WM
  • Figure 13: Trial locations in WM
  • Figure 14: WM trials status
  • Figure 15: WM trials sponsors, by phase

LIST OF TABLES

  • Table 1: Incident cases of WM, 2017-26
  • Table 2: Incident cases of WM, by gender, 2017
  • Table 3: Marketed drugs for WM
  • Table 4: Pipeline drugs for WM in the US
  • Table 5: Brukinsa for WM (December 16, 2019)
  • Table 6: Mavorixafor for WM (July 17, 2019)
  • Table 7: Historical global sales, by drug ($m), 2014-18
  • Table 8: Forecasted global sales, by drug ($m), 2020-24